SCHEMBL1782510

SCHEMBL1782510

O=C1c2ccc(S(=O)(=O)O)cc2C(=O)c2cc(S(=O)(=O)O)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.50
MAOA P21397 1/20 0.50
UGT1A1 P22309 1/20 0.50
MAOB P27338 1/20 0.50
ESR2 Q92731 1/20 0.50
PKM P14618 3/20 0.48
ALDH1A1 P00352 5/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
GAA P10253 1/20 0.47
HSD17B10 Q99714 2/20 0.47
LMNA P02545 1/20 0.46
STAT3 P40763 1/20 0.46
PKLR P30613 2/20 0.46
PARG Q86W56 2/20 0.46
APEX1 P27695 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29600607 1.00 ESR1 (0.50) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL517673 1.00 ESR1 (0.50) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL29445521 1.00 ESR1 (0.50) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL29352388 1.00 ESR1 (0.50) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL29490328 1.00 ESR1 (0.50) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL29561433 1.00 ESR1 (0.50) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL31059305 1.00 ESR1 (0.50) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL2018087 0.98 ESR1 (0.48) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL2154846 0.98 ESR1 (0.48) ESR1MAOAUGT1A1MAOBESR2
SCHEMBL5228890 0.98 ESR1 (0.48) ESR1MAOAUGT1A1MAOBESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587583-A1 COVALENTLY MODIFIED TEMPLATE-INDEPENDENT DNA POLYMERASE AND METHODS OF USE THEREOF The Charles Stark Draper Laboratory, Inc. (US) 2025-07-23 EP claimed
WO-2025101956-A2 CONTROL OF ENZYMATIC NUCLEIC ACID SYNTHESIS VIA ELECTROCHEMICAL MEANS THE CHARLES STARK DRAPER LABORATORY, INC. (US) 2025-05-15 WO claimed
WO-2025034696-A2 LOW CROSSOVER ION EXCHANGE MEMBRANES FOR REDOX FLOW BATTERIES UNIVERSITY OF SOUTH CAROLINA (US) 2025-02-13 WO claimed
CN-112151277-B Electrolytic capacitor and method for manufacturing electrolytic capacitor 松下知识产权经营株式会社 2025-01-10 CN claimed
US-20240429494-A1 PLASMONIC PHOTOELECTRODES FOR PHOTOELECTROCHEMICAL REDOX FLOW BATTERIES DEPARTMENT OF ENERGY 2024-12-26 US claimed
CN-118518868-A Immunosensor of vitamin B2, preparation method and application 中芯维康医疗科技(重庆)有限责任公司 2024-08-20 CN claimed
WO-2024059703-A1 COVALENTLY MODIFIED TEMPLATE-INDEPENDENT DNA POLYMERASE AND METHODS OF USE THEREOF THE CHARLES STARK DRAPER LABORATORY, INC. (US) 2024-03-21 WO claimed
EP-2901520-B1 SMALL ORGANIC MOLECULE BASED FLOW BATTERY HARVARD COLLEGE (US) 2023-11-29 EP claimed
US-11817554-B2 Supercapacitor based on polymer electrolyte containing Mo(IV) doped hydrogel IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-11-14 US claimed
CN-113637503-B Bimetallic FMG desulfurizing agent for wet oxidation desulfurization 曲靖大为焦化制供气有限公司 2023-10-20 CN claimed
EP-1565530-A1 PREPARATION OF BETA QUINACRIDONE PIGMENTS Ciba SC Holding AG (CH) 2005-08-24 EP claimed
US-6864371-B2 Preparation of beta quinacridone pigments CIBA SPECIALTY CHEMICALS CORPORATION (US) 2005-03-08 US claimed
WO-2004067642-A1 SYNTHESIS OF SMALL PARTICLE SIZE QUINACRIDONE OF BETA CRYSTAL PHASE CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-08-12 WO claimed
US-20040138457-A1 Preparation of beta quinacridone pigments CIBA SPECIALTY CHEMICALS CORP. 2004-07-15 US claimed
WO-2004048479-A1 PREPARATION OF BETA QUINACRIDONE PIGMENTS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-06-10 WO claimed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP claimed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 EP claimed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 WO claimed
US-4455364-A ETCHING RESISTANCE KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1984-06-19 US claimed
US-4098667-A Electrochemical method and device for producing oxygen SOCIETE GENERALE DE CONSTRUCTIONS ELECTRIQUES ET MECANIQUES "ALSTHOM ET CIE" (FR) 1978-07-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138457-A1 Preparation of beta quinacridone pigments PPOX, QDPR, NDUFB3 ESR1 4837/4885MAOA 138/4885UGT1A1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.